HC Wainwright & Co. Maintains Buy on LifeMD, Lowers Price Target to $9
HC Wainwright & Co. analyst Yi Chen maintains LifeMD (NASDAQ:LFMD) with a Buy and lowers the price target from $10 to $9.
Read original at benzingaStocks · News reference
LifeMD Lowers FY2026 Sales Guidance from $220.000M-$230.000M to $205.500M-$212.500M vs $222.046M Est
LifeMD (NASDAQ:LFMD) lowers FY2026 sales outlook from $220.000 million-$230.000 million to $205.500 million-$212.500 million vs $222.046 million estimate.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 5, 2026, 8:49 PM
- Checked
- Aug 5, 2026, 8:49 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
B. Riley Securities Maintains Buy on LifeMD, Lowers Price Target to $8
B. Riley Securities analyst William Woods maintains LifeMD (NASDAQ:LFMD) with a Buy and lowers the price target from $10 to $8.
Read original at benzingaLifeMD shares are trading lower after the company reported worse-than-expected Q2 financial results and lowered its FY2026 sales guidance. Also, the company issued Q3 sales guidance below estimates.
Read original at benzingaBTIG Maintains Buy on LifeMD, Lowers Price Target to $9
BTIG analyst David Larsen maintains LifeMD (NASDAQ:LFMD) with a Buy and lowers the price target from $10 to $9.
Read original at benzinga